"Apo AI(Milano) is a drug candidate with outstanding clinical and commercial potential," said Andrew Baum, president and chief executive officer of SemBioSys. "Manufacturing challenges have been a major impediment to drug development efforts. We have now shown that safflower Apo AI(Milano), which we believe can be produced in a cost effective manner, has the potential to allow for the full development and commercialization of this drug candidate. We expect that the data we have previously generated, together with the latest animal model data, will greatly facilitate and accelerate our partnership efforts for this program."
About Apo AI/Apo AI(Milano)
Apo AI is a naturally occurring human protein being developed as a cardiovascular therapy to stabilize and reverse atherosclerotic plaque deposition for the prevention and treatment of cardiovascular disease. Apo AI is believed by many clinicians to be the archetype for a new generation of cardiovascular drugs (HDL therapies). Apo AI is the major apolipoprotein associated with HDL, commonly referred to as "good cholesterol", which naturally removes plaque from arteries. Published studies have shown that Apo AI(Milano), which is a variant of Apo AI, in a phospholipid formulation could reduce plaque volume at a level and speed unattainable with any current drug therapy. If successfully commercialized, predicted high dosing (multiple grams per course of patient treatment) coupled with a large patient population would be expected to drive volume demand of several tons of Apo AI(Milano) per year, underscoring the value of a highly scalable, plant manufacturing solution. SemBioSys' proprietary safflower derived Apo AI(Milano) is a des I, 2 variant of Apo AI(Milano) as previously described in the literature.
About Cardiovascular Disease
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved